Categories: News

Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program

Nerivio is the First Migraine Treatment Device Offered to Costco Prescription Program Members

NETANYA, Israel and MONTCLAIR, N.J., June 1, 2022 /PRNewswire/ — Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Costco Members Prescription Program (CMPP) is now offering Theranica’s FDA-cleared flagship product Nerivio® at an exclusive rate to Costco Members, marking the first time a migraine treatment device is offered to CMPP members.

Nerivio is an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in individuals aged 12 and older. Worn on the upper arm at the onset of a migraine attack, Nerivio alleviates migraine headache and associated symptoms by utilizing remote electrical neuromodulation to trigger an endogenous analgesic mechanism, known as conditioned pain modulation. Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options and can be used as a standalone treatment or in combination with existing treatments.

“This collaboration with Costco is a major step in helping us bring effective drug-free migraine relief to the millions of teens and adults in need,” said Alon Ironi, CEO of Theranica. “With its outstanding direct-to-customer policy, Costco is giving millions of under-insured and non-insured people affordable access to top quality prescription therapies, offering Nerivio as a first-line therapy. Moreover, the CMPP website helps members quickly receive a Nerivio prescription online, via a telemedicine consultation with a trained provider.”

The CMPP is a drug discount program that provides Costco members and their dependents the ability to obtain lower prices on prescription medications at participating pharmacies. All Costco members now gain access to Nerivio at an exclusive price, following a prescription from their health care provider or via a telemedicine consultation, and fulfilled by Miller’s Pharmacy online. Controlled by a smartphone app, Nerivio allows patients to treat their migraine attacks and monitor their results through a built-in migraine diary that is easily shared with healthcare providers for improved disease management.

“Tens of millions of Americans suffer from migraine and offering Nerivio to CMPP members supports our mission of providing safe, effective and clinically-validated relief to as many people as possible,” said Jen Stanton, Executive Director of Market Access at Theranica. “We are hopeful this will serve as a source of inspiration for other large retailers to bridge the gap between their customers and the effective migraine treatment they need.”

About Theranica

Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low-side effect therapies for idiopathic pain conditions. The company’s award-winning flagship product, Nerivio®, is the first FDA-cleared smartphone-controlled prescribed wearable device for acute treatment of migraine, and already serves over 30,000 people with migraine in the USA, including adolescents and veterans. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions. Nerivio has received FDA authorization and CE mark for use in acute treatment of episodic and chronic migraine in adult and adolescent patients.

Learn more by visiting our websites, theranica.com, nerivio.com and following us on LinkedIn, Twitter, Instagram and Facebook.

Theranica Contact:
Ronen Jashek
ronenj@theranica.com
+972-72-390-9750

Media Contact
Nechama Feuerstein
FINN Partners
Nechama.Feuerstein@finnpartners.com
+1-929-222-8006

 

View original content:https://www.prnewswire.com/news-releases/costco-wholesale-corporation-adds-nerivio-to-its-member-prescription-program-301558930.html

SOURCE Theranica

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

6 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

9 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

9 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

9 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

9 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

9 hours ago